Does elevated estrone with postmenopausal-range estradiol reflect peripheral production after menopause?

Following menopause, the cessation of ovarian follicular activity shifts the primary site of estrogen synthesis from the ovaries to extragonadal peripheral tissues.

Mechanistic pathways of estrogen synthesis

• Substrate conversion: Adrenal androgen precursors, primarily androstenedione along with upstream dehydroepiandrosterone (DHEA) and DHEA-S, serve as the primary substrates for peripheral estrogen synthesis.
• Aromatase pathway: Within the stromal cells of white adipose tissue, muscle, and skin, the aromatase enzyme (CYP19A1) catalyzes the conversion of androstenedione to estrone (E1) using molecular oxygen and NADPH.
• Increased conversion efficiency: The fractional conversion of androstenedione to estrone increases from approximately 1% in premenopausal women to 2–3% postmenopausally. Increased adipose tissue mass further elevates this capacity.
• Downstream metabolism: While peripheral tissues can convert estrone to estradiol (E2) via the action of 17β-hydroxysteroid dehydrogenase (17β-HSD), the overall postmenopausal endocrine profile remains heavily estrone-dominant.

Clinical differentiation of estrogen excess

• Reference ranges: Normal postmenopausal cessation of ovarian function results in circulating estradiol levels dropping to a low reference range of less than 10–20 pg/mL.
• Excluding ovarian hyperfunction: Generalized ovarian hypersecretion or estrogen-producing neoplasms, such as granulosa cell tumors, characteristically elevate estradiol levels well above the postmenopausal range.
• Interpretation of discordant values: Finding elevated estrone in the presence of postmenopausal-range estradiol (<10–20 pg/mL) indicates localized, estrone-specific peripheral aromatization of adrenal precursors—often linked to body mass—rather than active ovarian estrogen excess.

Bottom line

• An elevated estrone level coexisting with postmenopausal-range estradiol (<10–20 pg/mL) indicates peripheral aromatization of adrenal androgen precursors (typically driven by adipose tissue mass) rather than generalized ovarian estrogen excess.